LamdaGen Corporation, a privately-owned company focused on the development and commercialization of plasmonic biosensor systems for Point of Care (POC) diagnostics, announced today the Indian Patent Office has granted and recorded patent 360405 titled ENZYMATIC ASSAY FOR LSPR which enables high sensitivity and quantitative POC diagnostic testing. This patent is an important element of the Company’s expanding global patent portfolio and patent applications that protect LamdaGen’s Plasmonic Amplification Technology (PAT) immunoassay-based diagnostic technologies.
“We are pleased with the Indian grant which completes this global patent family. These patents broadly protect LamdaGen’s ability to perform ELISAs on any active Localized Surface Plasmon Resonance (LSPR) surface,” commented Randolph Storer, CEO and co-founder of LamdaGen Corporation. “This assay technique enables a powerful double-amplified plasmonic signal that yields remarkably deep sensitivities for use in high-sensitivity diagnostic detection.”
The Company’s digital PAT system is central to its LAuRA Diagnostic Platform. This rapid immuno-based POC system couples the high sensitivity and quantitation of lab-based ELISA tests with the simplicity and speed of lateral flow assays (LFA). The easy to use and economical system is ideal for greatly expanding access to high sensitivity and mobile diagnostic testing across multiple health sectors and geographies.
About LamdaGen Corporation
LamdaGen Corporation is a Silicon Valley developer of nano-based biosensors and powerful testing systems. The company’s mission is to develop and commercialize innovative technologies for disease detection wherever, and whenever, they are needed. We do this by focusing on providing high sensitivity global point of care diagnostics that are fast, simple and accessible to improve human health and wellness. For additional information, please visit www.LamdaGen.com or email 4info@LamdaGen.com